IRCT20221222056891N1 IRCT 2023-01-13 Pak Emirates Military Hospital Permethrin and Ivermectin in the Scabies Treatment Comparison Of Efficacy Of Single Application Topical 5% Permethrin Versus Single Dose Oral Ivermectin In The Treatment Of Scabies 2021-01-01 anticipated 60 Complete https://irct.ir/trial/67571 interventional Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: Randomization was conducted through sequentially numbered opaque envelopes generated from a random numbers table into two groups of 30 patients each. Each patient was assigned a number at enrollment which defined a study assignment (Topical 5% Permethrin versus Oral Ivermectin).Method of randomization was simple and unit individual. N/A Scabies. Intervention 1: Intervention group: Permethrin Group(A): 30 patients fulfilling inclusion criteria were prescribed permethrin 5% cream. They were asked to apply the cream to whole body covering neck to toe. After application patient were to wear clothes. They were explained that the cream must remain in contact with the skin for at least 12 hours and not to take bath before 12 hours after application. Patients were asked to take bath after 12 hrs . If any other family member was having similar symptoms he was also prescribed same medication. Patients were evaluated at week 1,2 and 4 after the treatment for resolution of pruritus and scabietic lesions and development of any adverse effects. Intervention 2: Intervention group: Intervention group(B): 30 patients fulfilling inclusion criteria received oral ivermectin 200ug/kg( Tab Ivermite) single dose only and were evaluated at week 1,2 and 4 after the treatment for resolution of pruritus and scabietic lesions and development of any adverse effects. Yes - There is a plan to make this available What will be shared: Deidentified Individual participant data like age, weight, duration of disease, gender, given drug and response to treatment will be shared. Efficacy with respect to duration of disease, gender, age and weight will also be provided. When: Data will be shared after the publication of the article likely by end of 2023. To whom: To the people associated with medical profession. Conditions: Documents would be used for educational purposes and will be shared by mail and will be entertained by primary researcher. Where to obtain: Data could be obtained from primary researcher as well as from Department of dermatology pak Emirates Military Hospital. How to obtain: Data could be obtained by mail and in person from hospital after approval from competent authority. Comments: